Skip to Main Content
Contribute Try STAT+ Today

Put aside for a moment the curiosity of why anyone would believe aspirin and fish oil might be an effective treatment for Duchenne muscular dystrophy, a rare, degenerative disease. There’s a more useful lesson from Monday evening’s Catabasis Pharma blowup: No amount of spinning bad data will turn a failed drug into an effective one.

Catabasis said its experimental drug, called edasalonexent, did not improve the muscle function of patients with Duchenne muscular dystrophy compared to a placebo. The outcome of the Phase 3 study is the end for the drug, and quite likely the entire company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • -xent is not on the list of FDA approved suffixes/endings for generic drugs (at least according to wikipedia Strange, it makes it sound like a bonified drug rather than a combination of fish oil and aspirin). I wonder how it got that official non-propriatary name. Or, is it an official name.

    • I believe it could have that name because it was still classified as an NCE despite being formulated from two generic products.

Comments are closed.